Literature DB >> 28316104

Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.

Stavros Stavrakis1, Zain Asad1, Dwight Reynolds1.   

Abstract

BACKGROUND: Implantable cardioverter defibrillators (ICDs) improve survival in patients with heart failure due to ischemic cardiomyopathy, but their benefit in nonischemic cardiomyopathy (NICM) has been recently questioned. We performed a meta-analysis of randomized clinical trials to examine the effect of ICDs on total mortality and arrhythmic death in patients with NICM. We also examined the impact of age and cardiac resynchronization therapy (CRT) on the relative effect of ICD compared to control. METHODS AND
RESULTS: We searched the MEDLINE and EMBASE databases for randomized trials evaluating the effect of ICD versus control in patients with NICM. Hazard ratios (HR) with 95% confidence interval (CI) were calculated using a random effects model. Six trials involving 2,967 patients were included (ICD, n = 1,553; control, n = 1,414). Based on the pooled estimate across the six studies, the use of ICD was associated with a significant reduction in total mortality (HR = 0.78, 95% CI 0.66-0.92; P = 0.003), as well as arrhythmic death (HR = 0.46, 95% CI 0.29-0.71; P = 0.0005) compared to control. ICD decreased total mortality in younger patients compared to control (HR = 0.63, 95% CI 0.46-0.86; P = 0.004), but not in older patients (HR = 0.97, 95% CI 0.56-1.68; P = 0.92). In patients with CRT, ICD reduced total mortality compared to control (HR = 0.78, 95% CI 0.65-0.95; P = 0.02), but not in patients with CRT (HR = 0.71, 95% CI 0.40-1.26).
CONCLUSIONS: ICDs decrease total mortality and arrhythmic deaths in patients with NICM. The benefit of ICD appears to be dependent on age and concomitant use of CRT.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  heart failure; implantable cardioverter defibrillator; mortality; nonischemic cardiomyopathy

Mesh:

Year:  2017        PMID: 28316104     DOI: 10.1111/jce.13204

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  13 in total

Review 1.  Should Primary Prevention ICDs Still Be Placed in Patients with Non-ischemic Cardiomyopathy? A Review of the Evidence.

Authors:  Harsha V Ganga; Abhishek Maan; E Kevin Heist
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

2.  Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary ICD Therapy.

Authors:  Craig R Narins; Mehmet K Aktas; Anita Y Chen; Scott McNitt; Fred S Ling; Arwa Younis; Wojciech Zareba; James P Daubert; David T Huang; Spencer Rosero; Valentina Kutyifa; Ilan Goldenberg
Journal:  JACC Clin Electrophysiol       Date:  2021-08-25

Review 3.  Implantable defibrillator therapy and mortality in patients with non-ischaemic dilated cardiomyopathy : An updated meta-analysis and effect on Dutch clinical practice by the Task Force of the Dutch Society of Cardiology.

Authors:  D A Theuns; T E Verstraelen; A C J van der Lingen; P P Delnoy; C P Allaart; L van Erven; A H Maass; K Vernooy; A A M Wilde; E Boersma; J G Meeder
Journal:  Neth Heart J       Date:  2022-09-06       Impact factor: 2.854

Review 4.  A Comparative Study Between Amiodarone and Implantable Cardioverter-Defibrillator in Decreasing Mortality From Sudden Cardiac Death in High-Risk Patients: A Systematic Review and Meta-Analysis.

Authors:  Hany A Zaki; Eman Shaban; Khalid Bashir; Haris Iftikhar; Adel Zahran; Waleed Salem; Amr Elmoheen
Journal:  Cureus       Date:  2022-06-16

5.  Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients-a systematic review and meta-analysis.

Authors:  Waqas Javed Siddiqui; Sandeep Aggarwal; Muhammad Rafique; Swaiman Singh; Steven Kutalek; Howard J Eisen
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

Review 6.  Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?

Authors:  Andrea Lorenzo Vecchi; Raffaele Abete; Jacopo Marazzato; Attilio Iacovoni; Andrea Mortara; Roberto De Ponti; Michele Senni
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

7.  Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in patients with dilated cardiomyopathy and heart failure without late gadolinium enhancement (LGE) cardiac magnetic resonance imaging (CMRI) high-risk markers - CRT-REALITY study - Study design and rationale.

Authors:  Milos Taborsky; Tomas Skala; Renata Aiglova; Marian Fedorco; Josef Kautzner; Tomas Jandik; Vlastimil Vancura; Ales Linhart; Martin Valek; Miloslav Novak; Petr Kala; Rostislav Polasek; Tomas Roubicek; Alexandr Schee; Gerhard Hindricks; Nikolaos Dagres; Robert Hatala; Jiri Jarkovsky
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2021-03-12       Impact factor: 1.245

8.  Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.

Authors:  Mohamad El Moheb; Johny Nicolas; Assem M Khamis; Ghida Iskandarani; Elie A Akl; Marwan Refaat
Journal:  Cochrane Database Syst Rev       Date:  2018-12-08

9.  Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.

Authors:  Tetz C Lee; Min Qian; Lan Mu; Marco R Di Tullio; Susan Graham; Douglas L Mann; Koki Nakanishi; John R Teerlink; Gregory Y H Lip; Ronald S Freudenberger; Ralph L Sacco; Jay P Mohr; Arthur J Labovitz; Piotr Ponikowski; Dirk J Lok; Conrado Estol; Stefan D Anker; Patrick M Pullicino; Richard Buchsbaum; Bruce Levin; John L P Thompson; Shunichi Homma; Siqin Ye
Journal:  ESC Heart Fail       Date:  2019-02-27

Review 10.  Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure.

Authors:  David Duncker; Christian Veltmann
Journal:  Curr Heart Fail Rep       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.